Literature DB >> 28369823

Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.

Masahito Tokunaga1, Kentaro Yonekura2, Daisuke Nakamura3, Kouichi Haraguchi4, Tomohisa Tabuchi5, Satoshi Fujino5, Maiko Hayashida5, Kenichi Maekawa5, Akihiko Arai4, Nobuaki Nakano1, Yuhei Kamada5, Ayumu Kubota1, Hirosaka Inoue5, Satsuki Owatari4, Shogo Takeuchi1, Yoshifusa Takatsuka1, Maki Otsuka4, Shuichi Hanada4, Tadashi Matsumoto3, Makoto Yoshimitsu5,6, Kenji Ishitsuka5,6, Atae Utsunomiya1.   

Abstract

Entities:  

Keywords:  CC chemokine receptor 4; adult T-cell leukaemia-lymphoma; cutaneous adverse reaction; mogamulizumab; prognostic factor

Mesh：

Substances：

Year:  2017        PMID： 28369823     DOI： 10.1111/bjh.14634

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.

Authors:  Jun Nakashima; Yoshitaka Imaizumi; Hiroaki Taniguchi; Koji Ando; Masako Iwanaga; Hidehiro Itonaga; Shinya Sato; Yasuhi Sawayama; Tomoko Hata; Shinichiro Yoshida; Yukiyoshi Moriuchi; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2018-07-21       Impact factor: 2.490

2.  Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.

Authors:  Kentaro Yonekura; Shigeru Kusumoto; Ilseung Choi; Nobuaki Nakano; Asahi Ito; Youko Suehiro; Yoshitaka Imaizumi; Makoto Yoshimitsu; Kisato Nosaka; Eiichi Ohtsuka; Michihiro Hidaka; Tatsuro Jo; Hidenori Sasaki; Yukiyoshi Moriuchi; Masao Ogata; Hiro Tatetsu; Kenji Ishitsuka; Yasushi Miyazaki; Ryuzo Ueda; Atae Utsunomiya; Takashi Ishida
Journal:  Blood Adv       Date:  2020-10-27

3.  Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kisato Nosaka; Bruce Crawford; Jingbo Yi; William Kuan; Tomoko Matsumoto; Takeshi Takahashi
Journal:  Eur J Haematol       Date:  2021-12-08       Impact factor: 3.674

Review 4.  Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Authors:  Megan H Trager; Donatienne de Clippelé; Caroline Ram-Wolff; Adèle de Masson; Marie-Dominique Vignon-Pennamen; Maxime Battistella; Laurence Michel; Martine Bagot; Gabor Dobos
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

Review 5.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

6.  Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kenji Ishitsuka; Satoshi Yurimoto; Yukie Tsuji; Manabu Iwabuchi; Takeshi Takahashi; Kensei Tobinai
Journal:  Eur J Haematol       Date:  2019-03-12       Impact factor: 2.997
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.